<< Common epigenetic problem doubles cancer risk | Proof that vaccinating children against influenza in the hope of reducing disease spread is inconclusive >>
Read in | English | Français | Finnish

NIH awards grant to explore causal relationship between epoetin dose and survival of hemodialysis patients

Published on February 27, 2005 at 5:12 AM · No Comments

The National Institutes of Health, National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) has awarded a two-year grant to the Medical Technology and Practice Patterns Institute (MTPPI) in collaboration with Harvard School of Public Health (HSPH) to explore the causal relationship between epoetin dose and survival of hemodialysis patients receiving this therapy.

Recent public attention has been directed toward the risks associated with certain drugs that are in wide-spread use. As with most drugs after FDA approval, assessment of the risks and clinical benefits of these products becomes very complicated because the relationship between drug use and patient outcomes is often confounded in complex ways that can not be addressed by conventional statistical techniques. Recently, researchers at Harvard School of Public Health (HSPH) have developed advanced statistical methods (referred to as marginal structural models - MSM) that adjust for such complex confounding practice patterns. In this grant, "Epoetin Therapy and Survival of Hemodialysis Patients," MSM techniques will be applied to explore the causal relationship of epoetin therapy for treatment of anemia on survival for hemodialysis patients. The application of these methods will provide a state-of-the-art estimate of the effect of epoetin on survival.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading